Quest Diagnostics Zukünftiges Wachstum
Future Kriterienprüfungen 1/6
Quest Diagnostics wird ein jährliches Gewinn- und Umsatzwachstum von 11.7% bzw. 4.8% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 11.1% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 15.5% betragen.
Wichtige Informationen
11.7%
Wachstumsrate der Gewinne
11.1%
EPS-Wachstumsrate
Healthcare Gewinnwachstum | 20.1% |
Wachstumsrate der Einnahmen | 4.8% |
Zukünftige Eigenkapitalrendite | 15.5% |
Analystenabdeckung | Good |
Zuletzt aktualisiert | 27 Oct 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Oct 25Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26Recent updates
Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Oct 25Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E
Oct 23Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Oct 15These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well
Aug 30Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Why Quest Diagnostics Isn't A 'Buy', My Oh My
Feb 14Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's
Feb 05Gewinn- und Umsatzwachstumsprognosen
Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
---|---|---|---|---|---|
12/31/2026 | 10,970 | 1,089 | 1,330 | 1,702 | 13 |
12/31/2025 | 10,608 | 1,001 | 1,090 | 1,484 | 16 |
12/31/2024 | 9,834 | 906 | 915 | 1,303 | 12 |
9/30/2024 | 9,539 | 838 | 1,023 | 1,397 | N/A |
6/30/2024 | 9,346 | 836 | 875 | 1,248 | N/A |
3/31/2024 | 9,287 | 842 | 947 | 1,332 | N/A |
12/31/2023 | 9,252 | 850 | 864 | 1,272 | N/A |
9/30/2023 | 9,297 | 759 | 596 | 1,079 | N/A |
6/30/2023 | 9,488 | 790 | 878 | 1,374 | N/A |
3/31/2023 | 9,603 | 789 | 864 | 1,332 | N/A |
12/31/2022 | 9,883 | 942 | 1,314 | 1,718 | N/A |
9/30/2022 | 10,294 | 1,230 | 1,464 | 1,865 | N/A |
6/30/2022 | 10,582 | 1,479 | 1,552 | 1,924 | N/A |
3/31/2022 | 10,679 | 1,874 | 1,602 | 1,982 | N/A |
12/31/2021 | 10,788 | 1,988 | 1,830 | 2,233 | N/A |
9/30/2021 | 11,046 | 2,175 | 1,872 | 2,293 | N/A |
6/30/2021 | 11,058 | 2,238 | 2,171 | 2,594 | N/A |
3/31/2021 | 10,335 | 1,794 | 2,068 | 2,489 | N/A |
12/31/2020 | 9,437 | 1,425 | 1,587 | 2,005 | N/A |
9/30/2020 | 8,361 | 1,101 | 1,384 | 1,812 | N/A |
6/30/2020 | 7,531 | 749 | 816 | 1,249 | N/A |
3/31/2020 | 7,657 | 771 | 779 | 1,215 | N/A |
12/31/2019 | 7,726 | 835 | 843 | 1,243 | N/A |
9/30/2019 | 7,639 | 709 | 811 | 1,190 | N/A |
6/30/2019 | 7,572 | 707 | 929 | 1,293 | N/A |
3/31/2019 | 7,538 | 720 | 938 | 1,295 | N/A |
12/31/2018 | 7,531 | 733 | 817 | 1,200 | N/A |
9/30/2018 | 7,557 | 860 | 914 | 1,228 | N/A |
6/30/2018 | 7,524 | 808 | N/A | 1,188 | N/A |
3/31/2018 | 7,469 | 782 | N/A | 1,159 | N/A |
12/31/2017 | 7,402 | 769 | N/A | 1,175 | N/A |
9/30/2017 | 7,398 | 671 | N/A | 1,156 | N/A |
6/30/2017 | 7,427 | 701 | N/A | 1,095 | N/A |
3/31/2017 | 7,469 | 702 | N/A | 1,112 | N/A |
12/31/2016 | 7,214 | 642 | N/A | 1,116 | N/A |
9/30/2016 | 7,503 | 675 | N/A | 1,037 | N/A |
6/30/2016 | 7,498 | 825 | N/A | 948 | N/A |
3/31/2016 | 7,517 | 748 | N/A | 922 | N/A |
12/31/2015 | 7,493 | 706 | N/A | 821 | N/A |
9/30/2015 | 7,527 | 703 | N/A | 852 | N/A |
6/30/2015 | 7,551 | 491 | N/A | 911 | N/A |
3/31/2015 | 7,528 | 507 | N/A | 906 | N/A |
12/31/2014 | 7,435 | 549 | N/A | 944 | N/A |
9/30/2014 | 7,308 | 506 | N/A | 845 | N/A |
6/30/2014 | 7,192 | 780 | N/A | 761 | N/A |
3/31/2014 | 7,105 | 799 | N/A | 689 | N/A |
12/31/2013 | 7,146 | 811 | N/A | 652 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: DGXDas prognostizierte Gewinnwachstum (11.7% pro Jahr) liegt über der Sparquote (2.5%).
Ertrag vs. Markt: DGXDie Erträge des Unternehmens (11.7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.4% pro Jahr).
Hohe Wachstumserträge: DGXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: DGXDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).
Hohe Wachstumseinnahmen: DGXDie Einnahmen des Unternehmens (4.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: DGXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (15.5%).